We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 17.50 | 0.98% | 1,798.00 | 1,798.00 | 1,798.50 | 1,798.50 | 1,780.00 | 1,784.00 | 2,314,251 | 16:02:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.97 | 73.8B |
From May 2019 to May 2024
LONDON-- GlaxoSmithKline PLC (GSK.LN) Tuesday said it has presented data from a phase III study of its investigational vaccine candidate for shingles, showing vaccine efficacy was maintained across age groups, from 50 years to 70 years and over.
Shares at 0955 GMT, down 17 pence, or 1.1%, at 1,545 pence valuing the company at GBP75.15 billion ($112.56 billion).
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
